Published in J Nucl Med on December 01, 2001
18F-NaF PET in Detecting Metastatic Bone Lesion for Patients With Cancer. | NCT00414934
Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging (2009) 1.87
Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy. Eur J Nucl Med Mol Imaging (2011) 1.63
Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging (2008) 1.54
The isotope bone scan: we can do better. Eur J Nucl Med Mol Imaging (2013) 1.39
Fluorinated tracers for imaging cancer with positron emission tomography. Eur J Nucl Med Mol Imaging (2004) 1.11
Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging (2013) 1.08
Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over? Adv Urol (2011) 1.05
Diagnosis of bone metastases: a meta-analysis comparing ¹⁸FDG PET, CT, MRI and bone scintigraphy. Eur Radiol (2011) 1.05
The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging (2016) 1.04
18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res (2011) 1.03
The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer. J Korean Med Sci (2009) 1.01
The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology. J Nucl Med (2012) 0.98
Assessment of successful incorporation of cages after cervical or lumbar intercorporal fusion with [(18)F]fluoride positron-emission tomography/computed tomography. Eur Spine J (2010) 0.95
Usefulness of (18)F-fluoride PET/CT in Breast Cancer Patients with Osteosclerotic Bone Metastases. Nucl Med Mol Imaging (2012) 0.90
Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging (2016) 0.89
Clinical Usefulness of (18)F-fluoride Bone PET. Nucl Med Mol Imaging (2010) 0.88
PET and PET/CT imaging of skeletal metastases. Cancer Imaging (2010) 0.88
Comparison of ¹⁸F-fluoride PET/CT, ¹⁸F-FDG PET/CT and bone scintigraphy (planar and SPECT) in detection of bone metastases of differentiated thyroid cancer: a pilot study. Br J Radiol (2014) 0.87
Therapeutic impact of [(18)F]fluoride positron-emission tomography/computed tomography on patients with unclear foot pain. Skeletal Radiol (2010) 0.86
(18)F and (18)FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation. Cancer Biol Ther (2008) 0.85
Molecular imaging in myeloma precursor disease. Semin Hematol (2011) 0.83
Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with (18)F-NaF PET/CT in castrate resistant prostate cancer patients. Am J Nucl Med Mol Imaging (2015) 0.82
Is 11C-choline the most appropriate tracer for prostate cancer? Against. Eur J Nucl Med Mol Imaging (2004) 0.81
Bone positron emission tomography with or without CT is more accurate than bone scan for detection of bone metastasis. Korean J Radiol (2013) 0.79
(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. Am J Nucl Med Mol Imaging (2014) 0.79
Comparison of standardized uptake values measured on F-NaF PET/CT scans using three different tube current intensities. Radiol Bras (2015) 0.78
Receiver operating characteristic (ROC) curve for classification of (18)F-NaF uptake on PET/CT. Radiol Bras (2016) 0.78
Unmet needs in the prediction and detection of metastases in prostate cancer. Oncologist (2013) 0.78
Prevalence of clinically significant extraosseous findings on unenhanced CT portions of ¹⁸F-fluoride PET/CT bone scans. ScientificWorldJournal (2012) 0.77
Complementary roles of tumour specific PET tracer ¹⁸F-FAMT to ¹⁸F-FDG PET/CT for the assessment of bone metastasis. Eur J Nucl Med Mol Imaging (2013) 0.77
Added value of using a cocktail of F-18 sodium fluoride and F-18 fluorodeoxyglucose in positron emission tomography/computed tomography for detecting bony metastasis: a case report. Medicine (Baltimore) (2015) 0.77
Sodium 18F-fluoride PET/CT of bone, joint, and other disorders. Semin Nucl Med (2015) 0.77
Optimal bone health management strategies in patients with prostate cancer. Indian J Urol (2013) 0.76
(18)F-NaF PET/CT: EANM procedure guidelines for bone imaging. Eur J Nucl Med Mol Imaging (2015) 0.76
Choline PET/CT compared with bone scintigraphy in the detection of bone metastases in prostate cancer patients. Eur J Nucl Med Mol Imaging (2012) 0.75
Combined 18F-fluoride and 18F-FDG PET/CT: a response based on actual data from prospective studies. Eur J Nucl Med Mol Imaging (2013) 0.75
Skeletal metastases: what is the future role for nuclear medicine? Eur J Nucl Med Mol Imaging (2009) 0.75
The role of 18F-NaF PET/CT in metastatic bone disease. J Bone Oncol (2015) 0.75
Metastatic mimics on bone scan: "All that glitters is not metastatic". Indian J Nucl Med (2016) 0.75
The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med (1994) 3.01
Comparative genome organization of vertebrates. The First International Workshop on Comparative Genome Organization. Mamm Genome (1996) 2.97
Treatment of ostial renal-artery stenoses with vascular endoprostheses after unsuccessful balloon angioplasty. N Engl J Med (1997) 2.34
Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med (2000) 2.15
Cryobiopsy increases the diagnostic yield of endobronchial biopsy: a multicentre trial. Eur Respir J (2011) 2.09
Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2. Neurology (2010) 1.84
Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol (2002) 1.72
Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol (1999) 1.58
Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med (1999) 1.53
Toll-like receptors regulate B cell cytokine production in patients with diabetes. Diabetologia (2010) 1.48
The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging (2007) 1.46
Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype. Cancer Res (1989) 1.41
Catabolism of 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) by isolated rat hearts. Eur J Nucl Med (1990) 1.39
Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med (1999) 1.35
Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation (1997) 1.34
An unusual case of Hughes-Stovin syndrome. Eur Respir J (1998) 1.33
2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer (2001) 1.30
Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging (2002) 1.28
Effect of local low-dose thrombolysis on clinical outcome in acute embolic renal artery occlusion. Radiology (1993) 1.27
2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology (1995) 1.24
Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut (1995) 1.23
FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med (1998) 1.22
Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med (2001) 1.22
Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings. Radiology (1998) 1.21
Alveolar liver echinococcosis: a comparative study of three imaging techniques. Infection (2001) 1.21
Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg (2000) 1.20
18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol (1998) 1.19
Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med (1997) 1.19
In vivo imaging of activated microglia using [11C]PK11195 and positron emission tomography in patients after ischemic stroke. Neuroreport (2000) 1.18
Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. AJR Am J Roentgenol (2001) 1.17
Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours. J Intern Med (2006) 1.15
Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin (2003) 1.14
Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol (1998) 1.11
Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas (2000) 1.10
Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology (1998) 1.09
Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med (1999) 1.08
Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? Eur J Nucl Med (1999) 1.08
Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology (1997) 1.08
Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med (2000) 1.07
Brain metastasis in lung cancer. Comparison of cerebral MRI and 18F-FDG-PET/CT for diagnosis in the initial staging. Nuklearmedizin (2010) 1.05
FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med (1999) 1.04
Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol (2012) 1.00
Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis. J Nucl Med (1998) 0.99
Diagnosis of ornithosis by cell culture and polymerase chain reaction in a patient with chronic pneumonia. Clin Infect Dis (1995) 0.99
MRI in the diagnosis of small bowel disease: use of positive and negative oral contrast media in combination with enteroclysis. Eur Radiol (2000) 0.98
Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med (2001) 0.98
Pericystic metabolic activity in alveolar echinococcosis: assessment and follow-up by positron emission tomography. Clin Infect Dis (1999) 0.98
[Imaging of the normal skeletal system with 18F Na-PET compared with conventional skeletal scintigraphy using Tc99m-MDP]. Rofo (1998) 0.97
Comparison of 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours. Eur J Nucl Med Mol Imaging (2012) 0.96
Effect on intimal hyperplasia of dexamethasone released from coated metal stents compared with non-coated stents in canine femoral arteries. Cardiovasc Intervent Radiol (1999) 0.96
Effects of bisoprolol on heart rate variability in heart failure. Am J Cardiol (1996) 0.94
Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol (2000) 0.94
Diagnostic imaging in Crohn's disease: comparison of magnetic resonance imaging and conventional imaging methods. Int J Colorectal Dis (2000) 0.94
Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma. Eur J Nucl Med (1999) 0.94
Noncavernomatous portal vein thrombosis in hepatic cirrhosis: treatment with transjugular intrahepatic portosystemic shunt and local thrombolysis. Radiology (1995) 0.94
Long-term follow-up of metabolic activity in human alveolar echinococcosis using FDG-PET. Nuklearmedizin (2008) 0.94
Molecular radiotherapy: the NUKFIT software for calculating the time-integrated activity coefficient. Med Phys (2013) 0.93
Decreased vaginal disease in J-chain-deficient mice following herpes simplex type 2 genital infection. Virology (2000) 0.92
HRCT-features of Pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients. Eur J Radiol (2011) 0.92
Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes. Ann Nutr Metab (1988) 0.92
The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk. Genet Epidemiol (1989) 0.92
Pre-operative staging of invasive breast cancer with MR mammography and/or PET: boon or bunk? Br J Radiol (2002) 0.90
[Lymph node staging of bladder neck carcinoma with positron emission tomography]. Urologe A (1999) 0.90
Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography. Thyroid (2001) 0.89
Positron emission tomography for detection and staging of malignant lymphoma. Recent Results Cancer Res (2000) 0.88
(18)F-FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and where we can go. Q J Nucl Med Mol Imaging (2011) 0.88
[PET and PET/CT in relapsing prostate carcinoma]. Urologe A (2006) 0.88
Validation of myocardial blood flow estimation with nitrogen-13 ammonia PET by the argon inert gas technique in humans. Eur J Nucl Med (2001) 0.88
C-11 methionine positron emission tomography/computed tomography localizes parathyroid adenomas in primary hyperparathyroidism. Horm Metab Res (2009) 0.87
[Positron emission tomography in diagnosis of renal cell carcinoma]. Urologe A (1996) 0.87
Percutaneous recanalization of iliac artery occlusions: results of a prospective study. Radiology (1993) 0.87
Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol (1999) 0.86
[MRI of the abdomen combined with enteroclysis in Crohn disease using oral and intravenous Gd-DTPA]. Radiologe (1998) 0.85
[18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions? J Thorac Cardiovasc Surg (2004) 0.85